Incyte

INCY · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

INCY · Last close · October 26, 2026

$113.31

Incyte's revenue rose 21.2% to $5.1 billion in fiscal 2025. Its operating margin was 29.5%, up from 1.4% a year earlier. Free cash flow was $1.4 billion, up 443.9%. The diluted share count fell 4.7%.

INCYTE CORPORATION Latest fiscal year ended December 31, 2025 10-K filed February 10, 2026 · 0000879169-26-000010 Updated October 9, 2026

Revenue

$5.1B

21.2%

Operating margin

29.5%

28.0 pts

Net income

$1.3B

3845.0%

Free cash flow

$1.4B

443.9%

Return on capital

79.4%

77.3 pts

Market cap

$23.4B

Oct 26 close

P/E

16.0x

On $7.08 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Incyte's 2018 10-K tags its long-term debt about a thousand times too large, so total debt is taken from the balance-sheet lines (its convertible notes). The last notes were repaid in 2020 and Incyte has had no borrowings since, so debt is zero from then.

Charts show fiscal years, from the 10-K filings.

Revenue and margins

Revenue

US$ billions, fiscal years

Margins

Percent of revenue

GrossOperatingNetFree cash flow

Net income and earnings per share

From fiscal 2016 to 2025, earnings per share grew 31.6% a year and net income 32.2% a year, as new shares raised the share count by 3% and diluted each share's earnings.

Net income

US$ billions, fiscal years; loss years in red.

Diluted earnings per share

US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity

Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.

Return on capitalReturn on equity

Cash flow

Free cash flow

US$ billions. Cash from operations minus capital expenditure; negative years in red.

Payouts and share count

Dividends and buybacks

US$ billions, cash paid in each fiscal year

DividendsShare buybacks

Diluted share count

Weighted-average diluted shares, millions

Valuation

Two ways to value Incyte yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.

Discounted cash flow (DCF)

A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Incyte's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.

Value per share on three example scenarios, from Incyte's fiscal 2025 free cash flow of $1.4B, net cash of $3.5B at December 31, 2025 and 201 million diluted shares, from its filings. The scenarios are fitted to Incyte: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 14.8% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 11% for a cyclical or higher-risk business (Biotechnology); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

From the filings

Starting free cash flow, US$ millions

Cash from operations minus capital spending in fiscal 2025.

Net cash, US$ millions

Cash and short-term investments minus debt and finance leases at December 31, 2025. Negative means net debt.

Diluted shares, millions

Weighted-average diluted shares in fiscal 2025.

Your assumptions

Start from

Fitted to Incyte's own revenue growth, as above. Cautious: growth of 7.5% then 5% a year, 2% after year 10, a 12% discount rate. Base: growth of 15% then 9% a year, 2.5% after year 10, a 11% discount rate. Optimistic: growth of 22.5% then 13% a year, 3% after year 10, a 10% discount rate.

Free cash flow growth, years 1 to 5 (% a year)

Free cash flow growth, years 6 to 10 (% a year)

Growth after year 10 (% a year)Long-run growth forever after year 10. Usually close to inflation, and always below the discount rate.

Discount rate (% a year)The yearly return an investor wants for the risk. A higher rate gives a lower value.

Value per share on these assumptions

—

Last close, October 26, 2026: $113.31
Value on these assumptions, against the last close: —

Cash flows in years 1 to 10, valued today: —
Everything after year 10, valued today: —
Plus net cash: —
Share of value from after year 10: —

Projected free cash flow

US$ billions. Each column is one year's projected free cash flow, split into what it is worth today and the part removed by discounting.

Value todayRemoved by discounting

How the value changes with two assumptions

Value per share in US$, with the growth rates above. The highlighted cell matches the current assumptions.

How the model works. Free cash flow grows at the first rate for five years and the second rate for five more, and each year is discounted at the discount rate. Everything after year 10 is valued as year-10 cash flow × (1 + growth after year 10) ÷ (discount rate − growth after year 10), discounted back ten years. Net cash is added and the total is divided by diluted shares. The result depends entirely on the assumptions. It is not a forecast, a price target or a recommendation. The last close is the consolidated US closing price, from Databento.

Price-to-earnings (P/E) method

Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.

Value per share on three example scenarios, from Incyte's earnings per share of $7.08 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 21.4×, the middle of Incyte's own P/E today, its peers' median and its sector's median (its peers' median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 12%, 11% and 10%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

Earnings per share, US$

Diluted earnings per share over the four quarters to March 31, 2026, from the 10-Qs and 10-K.

P/E multiple

P/E today is the last close divided by the latest earnings per share, the four quarters' where available. Peers: BioMarin Pharmaceutical, United Therapeutics, Neurocrine Biosciences.

Earnings growth in the years ahead (% a year) Starts at Incyte's revenue growth over the last 3 years, 14.8% a year, as the base scenario does.

Earnings per share in the years ahead, US$

Year 1Year 2Year 3Year 4Year 5

Type your own estimate for any year; the years after it carry on at the growth rate.

Apply the multiple to earnings

A multiple on a future year's earnings gives the price then, brought back to today at the discount rate below.

Discount rate (% a year) The yearly return an investor wants for the risk, as in the cash flow model.

Value per share today at this multiple

—

Last close, October 26, 2026: $113.31
Value at this multiple, against the last close: —
Incyte's P/E at the last close: 16.0×

Company	Last close	Earnings per share	P/E today
BioMarin PharmaceuticalBMRN	$55.75	$0.37	150.7×
Neurocrine BiosciencesNBIX	$145.87	$6.82	21.4×
United TherapeuticsUTHR	$592.84	$27.94	21.2×
IncyteINCY	$113.31	$7.08	16.0×

How the P/E method works. Value per share is earnings per share times the multiple. On a future year's earnings, that gives the price in that year, which is brought back to today at the discount rate: price ÷ (1 + discount rate) for each year ahead. It is quick and easy to compare across companies, but it ignores debt and cash, and earnings can swing with one-off gains and charges, so a multiple says most about steady, profitable businesses. Like the cash flow model, the result depends entirely on the assumptions you choose. It is not a forecast, a price target or a recommendation.

Balance sheet

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	2,348	3,239	3,656	2,158	3,581
Debt incl. finance leases	34	33	33	38	35
Net debt (negative means net cash)	−2,314	−3,206	−3,623	−2,120	−3,546
Net debt to EBITDA	−3.6x	−5.0x	−5.2x	−14.1x	−2.2x
Debt to equity	0.0x	0.0x	0.0x	0.0x	0.0x
Interest coverage	307.0x	217.3x	243.2x	26.9x	623.9x
Current ratio	3.6x	3.5x	3.8x	2.0x	3.3x
Quick ratio	3.6x	3.5x	3.7x	1.9x	3.2x

US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Insider trades

Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Incyte shares on the open market, and 10 insiders sold $58.3 million, all of it under trading plans set up in advance.

Date	Insider	Trade	Shares	Price	Value	Filing
Oct 15, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	2,642	$112.71	$297,780	Form 4
Sep 15, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	23,218	$120.49	$2.8 million	Form 4
Aug 19, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	10,801	$125.56	$1.4 million	Form 4
Aug 12, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	10,803	$120.04	$1.3 million	Form 4
Aug 5, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	10,640	$122.69	$1.3 million	Form 4
Aug 5, 2026	Patrick A MayesEVP & Chief Scientific Officer	Sold plan	2,207	$123.99	$273,646	Form 4
Aug 3, 2026	Patrick A MayesEVP & Chief Scientific Officer	Sold plan	6,055	$120.43	$729,204	Form 4
Jul 31, 2026	Patrick A MayesEVP & Chief Scientific Officer	Sold plan	41,899	$119.46	$5.0 million	Form 4
Jul 31, 2026	Pablo J CagnoniPresident, Global Head of R&D	Sold plan	15,888	$119.70	$1.9 million	Form 4
Jul 16, 2026	Steven H SteinCMO & Head of Late-Stage Dev.	Sold plan	1,877	$114.73	$215,348	Form 4
Jul 16, 2026	Mohamed Khairie IssaEVP, Head of U.S. Commercial	Sold plan	1,093	$115.01	$125,706	Form 4
Jul 15, 2026	Steven H SteinCMO & Head of Late-Stage Dev.	Sold plan	28,237	$113.05	$3.2 million	Form 4

The latest 12 of 35 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Piotroski F-score

The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.

Test	FY23	FY24	FY25
Net income is positive	Pass	Pass	Pass
Cash from operations is positive	Pass	Pass	Pass
Return on assets rose	Pass	Fail	Pass
Cash from operations exceeds net income	Fail	Pass	Pass
Debt fell relative to assets	Fail	Fail	Fail
Current ratio rose	Pass	Fail	Pass
Share count didn't rise	Fail	Pass	Pass
Gross margin rose	Fail	Fail	Pass
Revenue rose relative to assets	Fail	Fail	Pass
F-score	4 of 9	4 of 9	8 of 9
Accruals ratio	1.6%	−5.0%	−2.0%

The accruals ratio is net income minus cash from operations, over average total assets.

Compare

Put Incyte side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

Company	Year	Revenue growth	Operating margin	Free cash flow margin	Return on capital	Net debt to EBITDA	F-score	Compare
Incyte	FY25	21.2%	29.5%	26.4%	79.4%	−2.2x	8
BioMarin Pharmaceutical	FY25	12.9%	12.7%	22.5%	5.8%	−2.0x	5	Compare
United Therapeutics	FY25	10.6%	46.9%	32.7%	—	—	—	Compare
BioNTech	FY25	4.3%	−49.0%	9.8%	—	—	—	Compare
Neurocrine Biosciences	FY25	21.4%	21.6%	26.2%	25.6%	−2.3x	6	Compare

Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score above.

10 years of figures

Fiscal year	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Revenue	1,106	1,536	1,882	2,159	2,667	2,986	3,395	3,696	4,241	5,141
Revenue growth	46.7%	38.9%	22.5%	14.7%	23.5%	12.0%	13.7%	8.9%	14.8%	21.2%
Gross profit	1,048	1,457	1,788	2,044	2,535	2,835	3,188	3,441	3,929	4,769
Research and development	582	1,326	1,198	1,154	2,216	1,458	1,586	1,628	2,607	2,050
Operating income	145	−243	129	402	−264	586	579	620	61	1,515
Net income	104	−313	110	447	−296	949	341	598	33	1,287
Diluted EPS (US$)	0.54	−1.53	0.51	2.05	−1.36	4.27	1.52	2.65	0.15	6.41
Diluted shares (millions)	194	205	216	218	218	222	224	226	210	201
Cash flow
Cash from operations	305	−93	336	711	−125	750	970	496	335	1,414
Capital expenditure	120	111	74	78	187	181	78	32	86	59
Free cash flow	184	−204	263	633	−312	568	892	464	249	1,355
Dividends paid	0	0	0	0	0	0	0	0	0	0
Share buybacks	0	0	0	0	0	0	0	0	2,005	0
Acquisitions	143	0	0	0	0	0	0	0	0	0
Stock-based compensation	96	133	148	167	178	183	188	216	266	249
Balance sheet at fiscal year end
Cash and short-term investments	808	1,170	1,438	2,118	1,801	2,348	3,239	3,656	2,158	3,581
Debt incl. finance leases	652	24	17	51	35	34	33	33	38	35
Total assets	1,639	2,303	2,646	3,427	3,561	4,933	5,841	6,782	5,444	6,958
Total liabilities	1,219	672	720	828	950	1,163	1,471	1,592	1,997	1,790
Shareholders' equity	420	1,631	1,926	2,598	2,611	3,770	4,370	5,190	3,448	5,168
Margins and ratios
Gross margin	94.7%	94.8%	95.0%	94.7%	95.1%	94.9%	93.9%	93.1%	92.6%	92.8%
Operating margin	13.1%	−15.8%	6.9%	18.6%	−9.9%	19.6%	17.1%	16.8%	1.4%	29.5%
Net margin	9.4%	−20.4%	5.8%	20.7%	−11.1%	31.8%	10.0%	16.2%	0.8%	25.0%
Free cash flow margin	16.7%	−13.3%	14.0%	29.3%	−11.7%	19.0%	26.3%	12.6%	5.9%	26.4%
Return on capital	59.2%	−51.5%	24.8%	71.2%	−30.3%	50.9%	28.5%	32.6%	2.1%	79.4%
Return on equity	35.3%	−30.6%	6.2%	19.8%	−11.3%	29.7%	8.4%	12.5%	0.8%	29.9%
Return on assets	7.9%	−15.9%	4.4%	14.7%	−8.5%	22.3%	6.3%	9.5%	0.5%	20.8%
Net debt to EBITDA	−0.8x	—	−7.7x	−4.5x	—	−3.6x	−5.0x	−5.2x	−14.1x	−2.2x

US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)

Source: Incyte's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Incyte.